Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

British Patient Capital

Overview

Investments

Unlock datapoints

Portfolio analytics

Team

News & Media

Add fund to favorites
info
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 30
Average round size
info
The average size of a deal this fund participated in
$65M
Portfolio companies 24
Lead investments 3
Follow on index
info
How often the fund supports its portfolio startups at next rounds
0.20
Exits 1
Key employees Soon

Areas of investment

  • Biotechnology
  • Health Care
  • Therapeutics
  • Compliance
  • FinTech

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of British Patient Capital:
Typical Co-investors
British Patient Capital is more likely to invest in rounds together with the following funds:
There are no funds here. If we find new data, we will add it here.
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after British Patient Capital:
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Alcatel-Lucent Boulogne-Billancourt, France, Ile-de-France
Bestar Consultant Beijing, Beijing, China
Book.weibo.com -
Green D Ventures Boston, Massachusetts, United States
Guokai Ronghua -
infinitas capital Basel, Basel-Stadt, Switzerland
Ironweed Capital California, Palo Alto, United States
ITS Group Boulogne-Billancourt, France, Ile-de-France
LongLine Capital Beijing, Beijing, China
Mango V Foundation -
McConnell Venture Partners Charlotte, North Carolina, United States
McKenna Ventures Chicago, Illinois, United States
Murata Manufacturing Japan, Kyoto, Kyoto Prefecture
Oita Venture Capital Japan, Oita, Oita Prefecture
PCRS Corp California, Long Beach, United States
Refex Capital Fund Chennai, India, Tamil Nadu
Twilight Venture Partners Indiana, Indianapolis, United States
Venture Capital Action Plan -

Notable deals

CompanyIndustryRound SizeDateInvestorsLocation

Purespring Therapeutics

Biotechnology
Medical
09 Oct 2024 London, England, United Kingdom

Form3

Banking
Financial Services
FinTech
Mobile Payments
Payments
$63M10 Sep 2024 London, England, United Kingdom

IGEM Therapeutics

Biotechnology
Genetics
Therapeutics
$17M09 Sep 2024 London, England, United Kingdom

Myricx Pharma

Biotechnology
Life Science
$123M08 Jul 2024 United Kingdom, England, United Kingdom

Grey Wolf Therapeutics

Biotechnology
Health Care
Therapeutics
$50M23 May 2024 Oxford, England, United Kingdom

Curve Therapeutics

$55M27 Feb 2024 Southampton, Hampshire, United Kingdom

Tenpoint Therapeutics

Biotechnology
Product Research
$70M12 Jul 2023 Cornwall, England, United Kingdom

OMass Technologies

Life Science
Pharmaceutical
$13M15 May 2023 Oxford, England, United Kingdom

CyberSmart

Compliance
Cyber Security
Network Security
SaaS
$17M23 Feb 2023 London, England, United Kingdom
News
Quantexa raises $153M to build out AI-based big data tools to track risk and run investigations

– Quantexa, a London-based AI startup, raised $153m in Series D funding.
– The round was led by Warburg Pincus and joined by existing investors Dawn Capital, AlbionVC, Evolution Equity Partners (a specialist cybersecurity VC), HSBC, ABN AMRO Ventures and British Patient Capital.
– The company was valued between $800m and $900m.
– Quantexa got its start out of a gap in the market that Marria identified when he was working as a director at Ernst & Young tasked with helping its clients with money laundering and other fraudulent activity.
– It has now raised over $240m to date.

Review

  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Coinvestors
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent British Patient Capital?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 30
Average round size 65M
Peak activity year 2024
Lead investments 3
Follow on index 0.20
Exits 1
Group Appearance index 0.97

Latest deals

CompanyIndustryRound SizeDateInvestorsLocation

Purespring Therapeutics

Biotechnology
Medical
09 Oct 2024 London, England, United Kingdom

Form3

Banking
Financial Services
FinTech
Mobile Payments
Payments
$63M10 Sep 2024 London, England, United Kingdom

IGEM Therapeutics

Biotechnology
Genetics
Therapeutics
$17M09 Sep 2024 London, England, United Kingdom

Myricx Pharma

Biotechnology
Life Science
$123M08 Jul 2024 United Kingdom, England, United Kingdom

Grey Wolf Therapeutics

Biotechnology
Health Care
Therapeutics
$50M23 May 2024 Oxford, England, United Kingdom

Curve Therapeutics

$55M27 Feb 2024 Southampton, Hampshire, United Kingdom

Tenpoint Therapeutics

Biotechnology
Product Research
$70M12 Jul 2023 Cornwall, England, United Kingdom

OMass Technologies

Life Science
Pharmaceutical
$13M15 May 2023 Oxford, England, United Kingdom

CyberSmart

Compliance
Cyber Security
Network Security
SaaS
$17M23 Feb 2023 London, England, United Kingdom
Crunchbase icon

Content report

The following text will be sent to our editors: